News
Dr. Kenneth Mugridge appointed
23.04.2009 13:22 by Wolfgang Tiedke
Leipzig. The biopharmaceutical company BlackSwan Pharma GmbH, dedicated to the profiling and pre-clinical development of novel agents for the treatment of haematological cancers, announced today that the company has been strengthened by the appointment of Dr. Kenneth Mugridge into its consulting team. Dr. Mugridge has accumulated more than 30 years experience in pre-clinical drug discovery and development within pharmaceutical companies in the United Kingdom, Italy and Germany.
In the United Kingdom he was a member of the renowned research team at the Wellcome Research Laboratories led by Professor Sir John Vane, Nobel Laureate for Medicine in 1982, and Professor Salvador Monçada investigating the mechanism of action of non-steroidal anti-inflammatory drugs. In Italy he was positioned at the prestigious Sclavo Institute in Siena where he was in the team that discovered the anti-ulcer effects of the cytokine, IL-1, and also a series of anti-inflammatory peptides derived from the naturally occurring protein, annexin-1. Following a succession of senior roles in Italy´s largest ophthalmic-based company, SIFI SpA, Dr. Mugridge moved to Leipzig where he led teams at IBFB Pharma GmbH and Curacyte Discovery GmbH in the development of small-molecule entities for the treatment of COPD and psoriasis. Later, he was Project Leader of a research program in the area of chronic lymphocytic leukaemia (CLL) where his team had identified and characterized CD-160130 as a lead candidate for development. Dr. Mugridge´s previous expertise with small-molecule developments is anticipated to maintain and push forward the development timelines for CD-160130.
The technological base BlackSwan Pharma has been obtained through an exclusive and worldwide agreement with The Medicines Company (Leipzig) GmbH whereby both patent rights and scientific Know-How for the development of a novel series of small molecule apoptosis promoters has been agreed. The lead product, CD-160130, has received an Orphan Drug Designation from the European Commission.
In the United Kingdom he was a member of the renowned research team at the Wellcome Research Laboratories led by Professor Sir John Vane, Nobel Laureate for Medicine in 1982, and Professor Salvador Monçada investigating the mechanism of action of non-steroidal anti-inflammatory drugs. In Italy he was positioned at the prestigious Sclavo Institute in Siena where he was in the team that discovered the anti-ulcer effects of the cytokine, IL-1, and also a series of anti-inflammatory peptides derived from the naturally occurring protein, annexin-1. Following a succession of senior roles in Italy´s largest ophthalmic-based company, SIFI SpA, Dr. Mugridge moved to Leipzig where he led teams at IBFB Pharma GmbH and Curacyte Discovery GmbH in the development of small-molecule entities for the treatment of COPD and psoriasis. Later, he was Project Leader of a research program in the area of chronic lymphocytic leukaemia (CLL) where his team had identified and characterized CD-160130 as a lead candidate for development. Dr. Mugridge´s previous expertise with small-molecule developments is anticipated to maintain and push forward the development timelines for CD-160130.
The technological base BlackSwan Pharma has been obtained through an exclusive and worldwide agreement with The Medicines Company (Leipzig) GmbH whereby both patent rights and scientific Know-How for the development of a novel series of small molecule apoptosis promoters has been agreed. The lead product, CD-160130, has received an Orphan Drug Designation from the European Commission.
